Elevated Stratifin promotes cisplatin-based chemotherapy failure and poor prognosis in non-small cell lung cancer

Yu-Shui Ma; Li-Kun Hou; Shi-Hua Yao; Ji-Bin Liu; Xue-Chen Yu; Yi Shi; Xiao-Li Yang; Wei Wu; Chun-Yan Wu; Geng-Xi Jiang; Da Fu

Molecular Therapy: Oncolytics (Sep 2021)

Elevated Stratifin promotes cisplatin-based chemotherapy failure and poor prognosis in non-small cell lung cancer

Yu-Shui Ma,
Li-Kun Hou,
Shi-Hua Yao,
Ji-Bin Liu,
Xue-Chen Yu,
Yi Shi,
Xiao-Li Yang,
Wei Wu,
Chun-Yan Wu,
Geng-Xi Jiang,
Da Fu

Affiliations

Yu-Shui Ma: Department of Nuclear Medicine, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai 200072, China; Cancer Institute, Affiliated Tumor Hospital of Nantong University, Nantong 226631, China
Li-Kun Hou: Department of Pathology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China
Shi-Hua Yao: Department of Thoracic Surgery, Navy Military Medical University Affiliated Changhai Hospital, Shanghai 200433, China
Ji-Bin Liu: Cancer Institute, Affiliated Tumor Hospital of Nantong University, Nantong 226631, China
Xue-Chen Yu: Department of Mathematics, Statistics, and Computer Science, Macalester College, Saint Paul, MN 55105, USA
Yi Shi: Department of Nuclear Medicine, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai 200072, China
Xiao-Li Yang: Department of Nuclear Medicine, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai 200072, China
Wei Wu: Department of Pathology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China
Chun-Yan Wu: Department of Pathology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China; Corresponding author: Chun-Yan Wu, Department of Pathology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China.
Geng-Xi Jiang: Department of Thoracic Surgery, Navy Military Medical University Affiliated Changhai Hospital, Shanghai 200433, China; Corresponding author: Geng-Xi Jiang, Department of Thoracic Surgery, Navy Military Medical University Affiliated Changhai Hospital, Shanghai 200433, China.
Da Fu: Department of Nuclear Medicine, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai 200072, China; Corresponding author: Da Fu, Department of Nuclear Medicine, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai 200072, China.

Journal volume & issue: Vol. 22
pp. 326 – 335

Abstract

Read online

Drug resistance is a key factor in the treatment failure of clinical non-small cell lung cancer (NSCLC) patients after adjuvant chemotherapy. Here, our results provide the first evidence that eukaryotic translation initiation factor 2b subunit delta (EIF2B4)-Stratifin (SFN) fusion and increased SFN expression are associated with chemotherapy tolerance and activation of the phosphatidylinositol 3 kinase/v-akt murine thymoma viral oncogene (PI3K/Akt) signaling pathway in NSCLC patients, suggesting that SFN might have potential prognostic value as a tumor biomarker for the prognosis of patients with NSCLC.

Published in Molecular Therapy: Oncolytics

ISSN: 2372-7705 (Online)
Publisher: Elsevier
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: http://www.cell.com/molecular-therapy-family/oncolytics/latest-content

About the journal

Abstract

Keywords